Related references
Note: Only part of the references are listed.Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis
G. HORNEFF et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Recombinant human activated protein C
Martin Hughes
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Drotrecogin alfa (activated) does not affect intracellular production of interleukin-6 and tumor necrosis factor-α in endotoxin-stimulated human monocytes
EG Czeslick et al.
ANESTHESIA AND ANALGESIA (2005)
Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure
JF Dhainaut et al.
CRITICAL CARE MEDICINE (2005)
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
JF Dhainaut et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis
M Brueckmann et al.
INFLAMMATION RESEARCH (2004)
Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes
M Brueckmann et al.
CYTOKINE (2004)
The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma
T Hensler et al.
SHOCK (2003)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
